April 17, 2019 – Emerson has acquired Bioproduction Group ( Bio-G ), a specialist in simulation, modeling, and scheduling software for biomanufacturing. Bio-G’s scheduling and modeling systems combined with Emerson’s life sciences technology and expertise portfolio will help companies bring therapies for cancer, diabetes and other illnesses to patients sooner.
By connecting analytics and modeling tools with data from automation and operations systems—including Emerson’s DeltaV distributed control system and Syncade manufacturing execution system—the scheduling software provides a unified view of operations, maintenance, quality, and corporate systems. Bio-G’s software will become a part of Emerson’s Plantweb digital ecosystem, an IIoT portfolio that expands digital intelligence to the entire manufacturing enterprise.
Bio-G’s Real-Time Modeling Systemprovides debottlenecking, capacity engineering, and technology transfer analytics to deliver an evaluation of a facility’s design.
The modeling framework accurately identifies and quantifies bottlenecks, as well as determines the effectiveness of proposed solutions across all areas of a manufacturing facility. This modeling system helps accelerate the process of bringing therapies from clinical trials to full-scale manufacturing to patients by validating a facility’s potential for manufacturing success.
About Emerson
Emerson is a global technology and engineering company providing solutions for customers in industrial, commercial, and residential markets. The Emerson Automation Solutions business helps process, hybrid, and discrete manufacturers maximize production, protect personnel and the environment
